Alpha Cognition Inc (ACOG)

Alpha Cognition reported full-year 2025 total revenue of $10.2 million, with $6.8 million from ZUNVEYL net product sales and $3.4 million in licensing revenue. Alpha Cognition received a U.S. patent for ALPHA-1062 for the treatment of traumatic brain injury. The company announced the issuance of an additional U.S. patent covering ZUNVEYL dosing regimens. Alpha Cognition executed a second national Pharmacy Benefit Manager (PBM) contract, expanding payer access for ZUNVEYL. Alpha Cognition announced its voluntary delisting from the Canadian Securities Exchange (CSE). The company announced the pricing of a $50 million upsized public offering and its listing on Nasdaq. Alpha Cognition announced positive interim pre-clinical data for ALPHA-1062 in a military-relevant model of repetitive mild traumatic brain injury. The company announced a partial exercise of its over-allotment option.

There is no explicit mention of demand seasonality for Alpha Cognition, Inc.'s products and services. The company's primary product, ZUNVEYL, targets Alzheimer's disease, a chronic condition, which typically does not exhibit strong seasonal demand fluctuations. The company has reported consistent growth in demand for ZUNVEYL, with increasing rates of repeat ordering, indicating its integration into routine management in long-term care.

Alpha Cognition, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The company's major commercial product is ZUNVEYL, an oral tablet formulation approved for the treatment of mild-to-moderate Alzheimer's disease. Alpha Cognition also has several preclinical development programs, including ZUNVEYL in combination with memantine, ALPHA-1062, ALPHA-0602, ALPHA-0702, and ALPHA-0802.

Alpha Cognition Inc. develops treatments for patients in the United States and Canada. The company's commercial strategy for ZUNVEYL primarily targets the long-term care market in the U.S. Alpha Cognition anticipates two product approvals outside the U.S. through its partner, CMS Pharma, in Asia. The company is headquartered in Vancouver, Canada.

Alpha Cognition's brand reputation appears to be positively influenced by the commercial launch of ZUNVEYL. The FDA approval of ZUNVEYL was a critical step, allowing the company to bring its lead product to market. The successful commercial launch of ZUNVEYL has contributed to a favorable reputation. Positive interim pre-clinical data for ALPHA-1062 could enhance the company's reputation in the neurodegenerative disease space. Receiving patents for ALPHA-1062 and for ZUNVEYL dosing regimens further solidifies the company's intellectual property. An exclusive licensing agreement for ZUNVEYL in China highlights global interest and potential for the company's products.

Alpha Cognition is owned by a mix of institutional shareholders (45.51%), Alpha Cognition insiders (17.62%), and retail investors (36.87%). Major institutional owners include Opaleye Management Inc., Solas Capital Management, LLC, AWM Investment Company, Inc., Cable Car Capital LP, Ikarian Capital LLC, Sphera Funds Management Ltd., Alyeska Investment Group LP, Boothbay Fund Management, Llc, Aristides Capital LLC and Cantor Fitzgerald, L.P.. Opaleye Management Inc. is the largest individual Alpha Cognition shareholder.